Severe Asthma ToolkitSevere Asthma Toolkit
HomeAboutSpecific PopulationsRegistriesContributorsContact
Twitter
  • What is Severe Asthma?
    • Overview
    • Definition
    • Prevalence & Burden
    • Pathophysiology
    • Symptoms
    • Severe Asthma Attacks / Exacerbations / Flare-ups
    • Asthma Phenotypes
  • Diagnosis & Assessment
    • Overview
    • Diagnosis Overview
    • Assessment Overview
    • Lung Function Assessments
    • Questionnaires
    • Allergy Assessments
    • Phenotyping
    • Bronchoscopy
    • Imaging
    • Occupational Asthma
  • Management
    • Overview
    • Asthma Education
      • About Severe Asthma
      • Asthma Pathophysiology
      • Medications Education
      • Self-Monitoring
      • Triggers
      • Review
    • Written Action Plans
    • Adherence
    • Inhaler Technique
    • Physical Activity & Exercise
    • Interdisciplinary Approach & Multidimensional Assessment
    • Referral
  • Medications
    • Overview
    • Relievers
    • Preventers / Controllers
    • Add-on Therapies
    • Monoclonal Antibodies
    • Bronchial Thermoplasty
  • Co-Morbidities
    • Overview
    • Pulmonary & Upper Airways
      • Allergic & Non-Allergic Rhinitis
      • Chronic Rhinosinusitis
      • Dysfunctional Breathing
      • Vocal Cord Dysfunction
      • Chronic Obstructive Pulmonary Disease
      • Bronchiectasis
      • Obstructive Sleep Apnoea
    • Extra-Pulmonary
      • Obesity
      • Anxiety & Depression
      • Gastro-oesophageal Reflux Disease (GORD)
      • Osteoporosis
      • Cardiovascular Disease & Metabolic Disease
  • Living with Severe Asthma
    • Overview
    • Daily Symptom Burden
    • Mental & Emotional Health
    • Intimacy & Relationships
    • Self-Management Support
    • Medication Use & Costs
    • Experience of Care
    • Experience of Asthma Attacks
    • Prognosis
  • Establishing a Clinic
    • Overview
    • Set-up
    • Staffing & Multidisciplinary Team Approach
    • Facilities
    • Delivery Approach
    • Tailored Referrals
    • Evaluation
    • Opportunities for Training & Research
    • Barriers & Hurdles
  • Paediatrics
    • Overview
    • Management in Paediatrics
    • Assessment in Paediatrics
    • Alternative Diagnosis & Co-Morbidities in Paediatrics
    • Psychosocial Issues in Paediatrics
    • Medications in Paediatrics
    • Asthma in the Adolescent Population
  • Resources
    • Overview
    • Clinic Recommendations
    • Infographics
    • Asthma Assessment Resources
    • Systematic & Multidimensional Assessment Resources
      • Airway Components
      • Comorbidity Components
      • Risk Factor Components
    • Translation & Implementation
    • Case Studies
    • Presentations
    • Videos
    • Relevant Links
    • Key References

Chronic Obstructive Pulmonary Disease

Home Co-Morbidities Pulmonary & Upper Airways Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

Unlike asthma, Chronic Obstructive Pulmonary Disease or COPD is defined with spirometry and is characterised by persistent airflow limitation with an FEV1/FVC ratio of <0.7 (GOLD 2022).  Furthermore, for a diagnosis of COPD the individual must have a history of exposure to noxious particles or gases (GOLD 2022).  It has become increasingly apparent that many patients with asthma have features of COPD and vice versa. For more information see the GINA / GOLD Asthma, COPD and Asthma-COPD Overlap Syndrome Resource

asthma copd overlap diagram

Prevalence

The prevalence of co-existent COPD in adult asthma populations is approximately 20% (Gibson et al. 2015).  Patients with asthma and co-existent COPD experience (Hardin et al. 2014):

copd infographic

Diagnosis

A useful stepwise approach to diagnosis and initial treatment has been developed in collaboration between GINA & GOLD. (The approach is available on page 17 – Box 4).

Asthma COPD

Image presented with permissions from GINA & GOLD. This sheet can also be downloaded here.

Treatment

There is little high-quality evidence to guide clinicians in treating patients with suspected COPD-asthma overlap.  Use of long acting beta agonists (LABAs) without inhaled corticosteroids is recommended as first line therapy in COPD (COPD-X Guidelines 2020), but should be avoided in patients with co-existent asthma due to potential harm (GINA 2022).

Long acting muscarinic antagonists (LAMAs) are an option in this patient population, given that there is evidence for their use in patients with COPD (COPD-X Guidelines 2020) and in patients with severe asthma (GINA 2022).

Pulmonary rehabilitation in symptomatic patients with COPD reduces exacerbations and improves exercise capacity and quality of life (COPD-X Guidelines 2020).  Whilst this intervention has not been well studied in patients with COPD and co-existent asthma, we suggest that symptomatic patients with impaired lung function due to with COPD and co-existent asthma should be considered for pulmonary rehabilitation.

In patients with severe allergic asthma and coexistent COPD, omalizumab the anti-IgE monoclonal antibody, has been found to improve asthma control and quality of life (Maltby et al. 2017).

Previous
Next
Click here to download a printable version of the infographic below.

Access the full suite of infographics here.

asthma COPD overlap infographic

Last Updated on October 3, 2022

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

More results...

  • Overview
  • Pulmonary & Upper Airways
    • Allergic & Non-Allergic Rhinitis
    • Chronic Rhinosinusitis
    • Dysfunctional Breathing
    • Vocal Cord Dysfunction
    • Chronic Obstructive Pulmonary Disease
    • Bronchiectasis
    • Obstructive Sleep Apnoea
  • Extra-Pulmonary
    • Obesity
    • Anxiety & Depression
    • Gastro-oesophageal Reflux Disease (GORD)
    • Osteoporosis
    • Cardiovascular Disease & Metabolic Disease
For considerations relevant to the paediatric and adolescent population, please see Alternative Diagnoses & Co-Morbidities in Paediatrics or Asthma in the Adolescent Population

We want to know who accesses the Severe Asthma Toolkit and how it is used. Please complete our survey.

Responses will inform the continued development of the Severe Asthma Toolkit and future translation and implementation activities. Any feedback you provide will be greatly appreciated.

Complete Survey

  • Website Terms of Use
  • Website Survey
© Copyright 2018    CRICOS Provider Number 00109J    The University of Newcastle, Australia